In one paragraphArticle in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Mykola PinkevychInfection Analytics Program, Kirby Institute for Infection and Immunity, UNSW Australia, Sydney, New South Wales, Australia.ORCID 0000-0002-7407-5131 Steffen S DockenInfection Analytics Program, Kirby Institute for Infection and Immunity, UNSW Australia, Sydney, New South Wales, Australia.ORCID 0000-0003-3771-5504 Yuhuang WuInfection Analytics Program, Kirby Institute for Infection and Immunity, UNSW Australia, Sydney, New South Wales, Australia.
Timothy SchlubInfection Analytics Program, Kirby Institute for Infection and Immunity, UNSW Australia, Sydney, New South Wales, Australia.ORCID 0000-0001-7746-9649 Justin L HarperDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-6948-3501 Elise G VioxDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-2788-4585 Sadia SamerDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.ORCID 0000-0001-8731-2573 Deanna KulpaDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-0411-7295 Michael R BettsDepartment of Microbiology and Center for AIDS Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-7690-1484 Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.ORCID 0000-0002-2381-1151 Mirko PaiardiniDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-7276-3600 Katharine J BarDepartment of Medicine and Center for AIDS Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-9773-0071 Deborah CromerInfection Analytics Program, Kirby Institute for Infection and Immunity, UNSW Australia, Sydney, New South Wales, Australia.
Miles P DavenportInfection Analytics Program, Kirby Institute for Infection and Immunity, UNSW Australia, Sydney, New South Wales, Australia.ORCID 0000-0002-4751-1831 Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0MViral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Matthew Ryan Gardner · 2018 to 2026
$17.5MProject 2 - Michael BettsP01AI131338 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BAR, KATHARINE JUNE, BETTS, MICHAEL R · 2017 to 2021
$7.8MImmune based interventions for HIV eradicationR01AI116379 · NIAID · EMORY UNIVERSITY · PI PAIARDINI, MIRKO · 2015 to 2019
$4.2MTargeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.R33AI116171 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI LEDERMAN, MICHAEL MARCEL, PAIARDINI, MIRKO · 2016 to 2018
$1.5MNational Health and Medical Research Council 2026360,1173528National Health and Medical Research Council 2034108,1173027NIAID NIH HHS P01 AI131338NIAID NIH HHS R01 AI116379NIAID NIH HHS R33 AI116171NIAID NIH HHS UM1 AI164562NIH HHS 75N91019D00024NIH HHS P01AI131338NIH HHS P01AI131338, R01AI116379, UM1AI164562, R21/R33AI116171NIH HHS P51 OD011132NIH HHS U42 OD011023
6 · The paper itselfAbstract
Active human immunodeficiency virus (HIV) replication generates long-lived latently infected cells that persist despite effective antiretroviral therapy (ART). Several studies analyzing proviral DNA sequences sampled during ART have shown that these sequences are closely related to plasma virus present around treatment initiation. However, a large proportion of proviral DNA is defective or difficult to reactivate, suggesting that only a subset of latent proviruses contributes to viral rebound IMPORTANCE: Human immunodeficiency virus infection cannot be eliminated because of long-lived, latently infected cells. Understanding when the latent reservoir forms may help identify the timing of interventions to reduce viral rebound. We analyzed data from macaques infected with a barcoded virus that allowed us to track individual viral lineages. Although many lineages were present in plasma during active infection, only a small number rebounded after antiretroviral treatment (ART) interruption. We compared barcode patterns in rebound virus with plasma virus sampled at different times before treatment to identify when rebounding lineages were observed. We found that the rebound virus was most closely related to the plasma virus present at treatment initiation, suggesting that this may be an important time for the formation of the rebound-initiating reservoir. Rebound virus matched pre-treatment plasma virus more closely than proviral DNA detected during ART, suggesting that on-treatment proviral DNA may poorly predict which viruses will re-emerge after treatment interruption.
Indexed as
Anti-Retroviral AgentsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsDNA, ViralHumansMacaca mulattaProvirusesTreatment InterruptionViral LoadVirus LatencyVirus ReplicationAnti-Retroviral AgentsDNA, ViralHIVlatencylatent reservoir formationSIVviral rebound
Identifiers
PMID42517631
PMCPMC13483457
What OpenQuestion holds
Textmetadata
Read underepoch 390